Key result
Prasugrel links to double the rate of in-hospital ADPri switching compared to clopidogrel.
Why the study?
Little is known about the frequency and factors associated with in-hospital switching between clopidogrel and prasugrel among patients with myocardial infarction treated with PCI in clinical practice.
What are the frequency and factors associated with in-hospital switching between clopidogrel and prasugrel in patients with acute myocardial infarction treated with percutaneous coronary intervention?
Observational (n=47,040)
Yes
What are the frequency and factors associated with in-hospital switching between clopidogrel and prasugrel in patients with acute myocardial infarction treated with percutaneous coronary intervention?
In-hospital switching between clopidogrel and prasugrel is relatively common and is driven by a combination of ischemic risk, bleeding risk, and medical drug coverage.
Answers are grounded in this paper and cite their sources.
Switching between ADP receptor inhibitors occurs with identifiable factors after MI PCI; leaves open whether patterns affect outcomes in practice.
BACKGROUND: Although randomized clinical trials have compared clopidogrel with higher potency ADP receptor inhibitors (ADPris) among patients with myocardial infarction, little is known about the frequency and factors associated with switching between ADPris in clinical practice. METHODS AND RESULTS: We studied 47 040 patients with myocardial infarction treated with percutaneous coronary intervention, who received either clopidogrel or prasugrel within 24 hours of admission at 361 US hospitals from July 2009 to June 2011 using the merged Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With the Guidelines and CathPCI Registry database. Hierarchical logistic regression modeling was used to determine factors independently associated with in-hospital ADPri switching. Among 40 531 patients treated initially in-hospital with clopidogrel, 2125 (5.2%) were discharged on prasugrel; this frequency steadily increased from 0% to 7% during the study period. Among 6509 patients treated initially in-hospital with prasugrel, 751 (11.5%) were discharged on clopidogrel. The frequency of this switch increased from 6% to 18% during the first 2 quarters of the study period and decreased to 9% by the end. Switching clopidogrel to prasugrel was associated with high-risk angiographic characteristics (thrombotic, long, and bifurcating lesions), reinfarction in-hospital, and private health insurance coverage. Older age, previous cerebrovascular event, in-hospital coronary artery bypass grafting, in-hospital bleeding, and warfarin use at discharge were associated with switching prasugrel to clopidogrel. CONCLUSIONS: Clopidogrel and prasugrel are not uncommonly switched in-hospital in patients with myocardial infarction undergoing percutaneous coronary intervention. In contemporary US practice, in addition to risk for bleeding and recurrent ischemic events, medical drug coverage is a major determinant of ADPri selection.
No takes yet. Share an insight, caveat, or question.
Bagai et al. (2014) conducted an observational in Acute Myocardial Infarction (n=47,040). In-hospital switching between clopidogrel and prasugrel vs. Continuation of initial therapy was evaluated on In-hospital ADPri switching. In-hospital switching of ADP receptor inhibitors occurred in 5.2% of patients initially treated with clopidogrel and 11.5% of those initially treated with prasugrel.
Synapse has enriched 10 related papers. Consider them for comparative context: